Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH)
in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
National Institutes of Health (NIH) Takeda Pharmaceuticals North America, Inc.